Page 7 - B Cells News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Of protection, something that says this is the measurement that one needs to know how well they are protected. and now with these variants, we're seeing how these antibody responses sort of take a hit. >> reporter: let's say you're in a situation where someone essentially doesn't have antibodies anymore. you don't see them. does that mean they no longer have protection? >> not necessarily. so, there's several aspects to one's immune system that can drive protection. >> reporter: like b cells, which can make more antibodies if the virus comes back. and t cells, which help activate the immune sy...

Protection, this is the measurement one needs to know how well they are protected. now with the variants, we're seeing how the antibody responses take a hit. >> let's say you're in a situation where someone essentially doesn't have antibodies anymore, you're to measure their antibodies you don't see them, does that mean they no longer have protection? >> not necessarily. there is several aspects to one's immune system that can drive protection. >> reporter: like b cells which can make more antibodies if the virus comes back and t cells which help activate the immune system and get rid of infec...

Protection. something that says this is the measurement one needs to know they are protected. now with these variants, we see how they take a hit. >> reporter: say someone essentially doesn't have antibodies anymore. does that mean they no longer have protection? . >> not necessarily. there are several aspects to one's immune system that can drive protection. >> reporter: like b cells, which can make more antibodies if the virus comes back. and t cells, which help activate the immune system and get rid of infected cells. antibodies in your blood naturally wane over time. think of it like secur...

Research suggests that too-frequent immunizations may lead to a phenomenon called “immune exhaustion.”

Move over, A: B is taking the lead now, with Be Biopharma closing out a $130 million financing round backed by several industry leaders that will fuel its engineered B cells platform.